Phase 1a1b Study of LY4175408 Antibody Drug in Adults with Advanced Solid Tumors Including Lung, Endometrial, and Triple Negative Breast Cancer

What this Trial Is About

This research aims to assess the safety and effectiveness of LY4175408 in adults with certain advanced or metastatic solid tumors, including non-small cell lung cancer, small cell lung cancer, endometrial cancer, and triple negative breast cancer. The study also investigates how LY4175408 is processed in the body, including its levels in the blood, breakdown, and elimination. Participants may be involved for up to four years. Participants receive LY4175408 through intravenous infusion in dose escalation and expansion phases. Some groups will receive LY4175408 alone, while others will receive it combined with pembrolizumab, and in some cases with carboplatin or cisplatin, also given intravenously. The study includes multiple cohorts with varying dosing schedules to evaluate safety, tolerability, and preliminary efficacy. During the trial, participants undergo regular assessments including monitoring for dose limiting toxicities within 21-day cycles and evaluations of response such as complete or partial tumor response over up to four years. Pharmacokinetic measurements track the drugs concentration in the blood during the first 84 days. Other measures include progression-free survival, disease control rate, duration and time to response. Safety and efficacy outcomes are closely followed throughout the participation period, which can last up to four years.

A Study of LY4175408 in Participants With Advanced Cancer